Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo

British Journal of Clinical Pharmacology

Volumn 48, Issue 5, 1999, Pages 663-668

  Larsen, J T ^a   Hansen, L L ^b   Brosen K ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b NONE

Author keywords

Caffeine metabolism; Cytochrome P4501A2; Metabolic probe; Tacrine metabolism; Variability

Indexed keywords

CAFFEINE; CYTOCHROME P450 ISOENZYME; TACRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOLINESTERASE INHIBITORS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; HUMANS; MALE; PHENOTYPE; TACRINE;

EID: 0032710101     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00079.x     Document Type: Article

References (35)

1. 1 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
2. 2 Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
3. 3 Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome (s) P-450 in human liver microsomes. Drug Metab Dispos 1987; 15: 237-249.
4. 4 Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43: 827-832.
5. 5 Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994; 22: 909-915.
6. 6 Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5: 259-274.
7. 7 Balogh A, Harder S, Vollandt R, Staib AH. Intra-individual variability of caffeine elimination in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1992; 30: 383-387.
8. 8 McQuilkin SH, Nierenberg DW, Bresnick E. Analysis of within subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. Cancer Epidemiol Biomarkers Prev 1995; 4: 139-146.
9. 9 Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
10. 10 Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
11. 11 Pool W, Bjorge S, Chang T, Woolf T. Metabolic disposition of the cognition activator tacrine in man: identification of phenol glucuronide metabolites in urine. ISSX Proceedings Fourth North American ISSX Meeting 1992-164.
12. 12 Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995; 23: 929-934.
13. 13 Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993; 46: 13-20.
14. 14 Woolf TF, Pool WF, Bjorge SM, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos 1993; 21: 874-882.
15. 15 Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619-627.
16. 16 Larsen JT, Hansen LL, Spigset O, Brosen K. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol 1999; 55: 375-382.
17. 17 Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
18. 18 Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6: 213-222.
19. 19 Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996; 18: 254-262.
20. 20 Rasmussen BB, Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Br J Clin Pharmacol 1997; 43: 253-258.
21. 21 Hansen LL, Larsen JT, Brosen K. Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and flourescence detection. J Chromatogr B 1998; 712: 183-191.
22. 22 Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-165.
23. 23 Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109-116.
24. 24 Fuhr U, Rost KL, Engelhardt R, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6: 159-176.
25. 25 Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994; 3: 413-421.
26. 26 Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995; 39: 65-69.
27. 27 Rostami Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149.
28. 28 Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23: 1429-1435.
29. 29 Fontana RJ, deVries TM, Woolf TF, et al. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Br J Clin Pharmacol 1998; 46: 221-228.
30. 30 Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41: 605-608.
31. 31 Walter Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31: 47-64.
32. 32 Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561-1568.
33. 33 Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha tocopherol. Pharmacogenetics 1997; 7: 11-19.
34. 34 Rowland M, Tozer T. Clinical pharmacokinetics - concepts and applications. 3rd edn. Baltimore: Williams & Wilkins 1995.
35. 35 Kalow W, Tang B-K, Endrenyi L. Hypothesis: Comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-289.